JAC Advance Access published online on January 19, 2005
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh531
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 University of Washington School of Medicine, and General Internal Medicine Clinic, VA Puget Sound Health Care System (S-111-GIMC), 1660 S. Columbian Way, Seattle, WA 98108-1597, USA
* To whom correspondence should be addressed. The predominant pathogens causing diabetic foot infections are Gram-positive cocci, many of which are now resistant to commonly prescribed antibiotics. Daptomycin is a new agent that is active against most Gram-positive pathogens. To compare the effectiveness of daptomycin against semi-synthetic penicillins or vancomycin, we analysed the subset of diabetic patients with an infected ulcer enrolled in two randomized, controlled investigator-blind trials of patients with complicated skin and soft-tissue infections presumptively caused by Gram-positive organisms. Patients with a diabetic ulcer infection were prospectively stratified to ensure they were equally represented in the treatment groups, then randomized to either daptomycin [4 mg/kg every 24 h intravenously (iv)] or a pre-selected comparator (vancomycin or a semi-synthetic penicillin) for 7-14 days. Among 133 patients with a diabetic ulcer infection, 103 were clinically evaluable; 47 received daptomycin and 56 received a comparator. Most infections were monomicrobial, and Staphylococcus aureus was the predominant pathogen. Success rates for patients treated with daptomycin or the comparators were not statistically different for clinical (66% versus 70%, respectively; 95% CI, -14.4, 21.8) or microbiological (overall or by pathogen) outcomes. Both treatments were generally well tolerated, with most adverse events of mild to moderate severity. The clinical and microbiological efficacy and safety of daptomycin were similar to those of commonly used comparator antibiotics for treating infected diabetic foot ulcers caused by Gram-positive pathogens. Daptomycin should be considered for treating these infections, especially those caused by resistant Gram-positive pathogens.
Received September 2, 2004
Revised November 9, 2004
Accepted November 10, 2004
Original article
Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections
2 Cubist Pharmaceuticals, Inc, Lexington, MA, USA
Benjamin A. Lipsky, E-mail: Benjamin.Lipsky{at}med.va.gov
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Kim, L. A. Suecof, C. A. Sutherland, L. Gao, J. L. Kuti, and D. P. Nicolau In Vivo Microdialysis Study of the Penetration of Daptomycin into Soft Tissues in Diabetic versus Healthy Volunteers Antimicrob. Agents Chemother., November 1, 2008; 52(11): 3941 - 3946. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Seaton Daptomycin: rationale and role in the management of skin and soft tissue infections J. Antimicrob. Chemother., November 1, 2008; 62(suppl_3): iii15 - iii23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Paladino, J. L. Sunderlin, M. H. Adelman, M. E. Singer, and J. J. Schentag Observations on vancomycin use in U.S. hospitals Am. J. Health Syst. Pharm., August 1, 2007; 64(15): 1633 - 1641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Lipsky, P. Giordano, S. Choudhri, and J. Song Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate J. Antimicrob. Chemother., August 1, 2007; 60(2): 370 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Credito, G. Lin, and P. C. Appelbaum Activity of Daptomycin Alone and in Combination with Rifampin and Gentamicin against Staphylococcus aureus Assessed by Time-Kill Methodology Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1504 - 1507. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Jevitt, G. M. Thorne, M. M. Traczewski, R. N. Jones, J. E. McGowan Jr., F. C. Tenover, and S. D. Brown Multicenter Evaluation of the Etest and Disk Diffusion Methods for Differentiating Daptomycin-Susceptible from Non-Daptomycin-Susceptible Staphylococcus aureus Isolates. J. Clin. Microbiol., September 1, 2006; 44(9): 3098 - 3104. [Abstract] [Full Text] [PDF]
|
|